Revenue (Disaggregation of Revenue by Product) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Revenue	$ 34,124.1	$ 28,541.4	$ 28,318.4
U.S.
Disaggregation of Revenue [Line Items]
Revenue	21,791.0	18,190.0	16,811.0
Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	12,333.1	10,351.3	11,507.4
Diabetes and Obesity | U.S.
Disaggregation of Revenue [Line Items]
Revenue	14,780.8	9,911.1	8,719.3
Diabetes and Obesity | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	4,886.8	4,553.7	4,468.8
Trulicity® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	5,433.3	5,688.8	4,914.4
Trulicity® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	1,699.2	1,750.9	1,557.6
Mounjaro® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	4,834.2	366.6	0.0
Mounjaro® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	328.9	115.9	0.0
Jardiance
Disaggregation of Revenue [Line Items]
Revenue	2,744.7	2,066.0	1,490.8
Jardiance | U.S.
Disaggregation of Revenue [Line Items]
Revenue	1,600.4	1,194.5	807.3
Jardiance | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	1,144.2	871.5	683.5
Humalog® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	863.2	1,191.9	1,320.7
Humalog® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	800.2	868.7	1,132.3
Humulin® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	610.1	730.2	832.9
Humulin® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	242.0	289.2	389.6
Basaglar
Disaggregation of Revenue [Line Items]
Revenue	728.3	760.4	892.5
Basaglar | U.S.
Disaggregation of Revenue [Line Items]
Revenue	443.1	470.7	588.3
Basaglar | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	285.2	289.7	304.2
Baqsimi | U.S.
Disaggregation of Revenue [Line Items]
Revenue	645.7	110.4	96.4
Baqsimi | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	31.9	28.9	16.8
Zepbound® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	175.8	0.0	0.0
Zepbound® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	0.0	0.0	0.0
Other diabetes and obesity | U.S.
Disaggregation of Revenue [Line Items]
Revenue	175.0	158.0	159.3
Other diabetes and obesity | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	355.2	338.9	384.8
Oncology | U.S.
Disaggregation of Revenue [Line Items]
Revenue	3,797.0	3,218.1	3,028.8
Oncology | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	2,861.3	2,448.1	2,712.5
Verzenio® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	2,509.0	1,653.2	834.9
Verzenio® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	1,354.3	830.3	515.0
Cyramza® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	402.3	351.4	358.1
Cyramza® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	572.4	620.0	674.8
Erbitux® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	528.9	500.1	481.8
Erbitux® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	67.6	66.4	66.4
Tyvyt®
Disaggregation of Revenue [Line Items]
Revenue	393.4	293.3	418.1
Tyvyt® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	0.0	0.0	0.0
Tyvyt® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	393.4	293.3	418.1
Alimta® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	72.9	543.7	1,233.9
Alimta® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	144.6	384.0	827.5
Other oncology | U.S.
Disaggregation of Revenue [Line Items]
Revenue	283.9	169.7	120.1
Other oncology | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	329.0	254.1	210.7
Immunology | U.S.
Disaggregation of Revenue [Line Items]
Revenue	2,057.9	1,892.8	1,881.8
Immunology | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	1,739.6	1,451.8	1,479.0
Taltz® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	1,831.6	1,724.6	1,542.4
Taltz® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	928.0	757.4	670.4
Olumiant
Disaggregation of Revenue [Line Items]
Revenue	922.6	830.5	1,115.1
Olumiant | U.S.
Disaggregation of Revenue [Line Items]
Revenue	225.5	148.2	324.1
Olumiant | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	697.2	682.3	791.0
Other immunology | U.S.
Disaggregation of Revenue [Line Items]
Revenue	0.8	20.0	15.3
Other immunology | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	114.4	12.1	17.6
Neuroscience | U.S.
Disaggregation of Revenue [Line Items]
Revenue	696.0	612.4	614.8
Neuroscience | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	2,182.5	933.8	1,283.7
Zyprexa® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	79.4	30.4	39.6
Zyprexa® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	1,615.4	306.5	390.7
Emgality® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	482.2	462.8	434.5
Emgality® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	196.0	188.1	142.7
Other neuroscience | U.S.
Disaggregation of Revenue [Line Items]
Revenue	134.4	119.2	140.7
Other neuroscience | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	371.1	439.2	750.3
Other | U.S.
Disaggregation of Revenue [Line Items]
Revenue	459.3	2,555.7	2,566.4
Other | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	662.9	964.0	1,563.5
Forteo® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	335.5	367.3	441.6
Forteo® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	197.7	245.8	360.3
Cialis® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	26.1	35.2	10.6
Cialis® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	355.3	552.1	707.9
COVID-19 antibodies
Disaggregation of Revenue [Line Items]
Revenue		2,020.0	2,240.0
COVID-19 antibodies | U.S.
Disaggregation of Revenue [Line Items]
Revenue	0.0	2,008.9	1,978.0
COVID-19 antibodies | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	0.0	14.7	261.4
Other | U.S.
Disaggregation of Revenue [Line Items]
Revenue	97.7	144.2	136.1
Other | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	$ 109.9	$ 151.3	$ 233.9